Aikaterini N. Tsouka
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Aikaterini N. Tsouka has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Alexandros D. Tselepis
Atherothrombosis Research Centre, Laboratory of Biochemistry, Department of Chemistry, University of Ioannina, 45110 Ioannina, Greece
5 shared publications - Ioannis K. Koutsaliaris
Atherothrombosis Research Centre, Laboratory of Biochemistry, Department of Chemistry, University of Ioannina, 45110 Ioannina, Greece
4 shared publications - Constantinos Tellis
Department of Chemistry, Division of Organic Chemistry and Biochemistry, School of Natural Sciences, University of Ioannina, Ioannina, Greece
3 shared publications - Aikaterini Gatsiou
Biosciences Institute, Vascular Biology and Medicine Theme, Faculty of Medical Sciences, Newcastle University, Newcastle Upon Tyne, UK
1 shared publication - Alexandra Barbouti
Department of Anatomy-Histology-Embryology, Faculty of Medicine, School of Health Sciences, University of Ioannina, 45110 Ioannina, Greece
1 shared publication Alexandros D. Tselepis
1 shared publication
Latest Publications
- Open Access
- 25 February 2026
- Published by MDPI AG in Lipidology
- Vol. 3 (1) , 8
The Effect of Lipoproteins on Platelet-Associated PCSK9 of Healthy Normolipidemic Volunteers: An In Vitro Study
Background: Proprotein convertase subtilisin/kexin type 9 (PCSK9) promotes low-density lipoprotein receptor degradation and thereby regulates plasma LDL cholesterol levels. Although PCSK9 is primarily produced by the liver, it has been detected in platelets; however, the origin and functional relevance of platelet-associated PCSK9 remain unclear. Methods: Washed platelets (WPs) were isolated from normolipidemic subjects. Endogenous platelet PCSK9 content was quantified by ELISA, and PCSK9 molecular forms were assessed by immunoblotting. The WPs were incubated with recombinant PCSK9 (recPCSK9), and platelet aggregation in response to arachidonic acid (AA) or thrombin (Thr) was evaluated. The effects of LDL- or HDL-bound PCSK9 on platelet aggregation were also examined. Results: Platelets from normolipidemic subjects contained measurable amounts of PCSK9 (0.84 ± 0.27 ng/mg protein), which increased to 2.91 ± 0.53 ng/mg protein following incubation with recPCSK9. Exposure to recPCSK9 significantly enhanced AA- and Thr-induced platelet aggregation. In contrast, LDL and HDL inhibited platelet aggregation independently of their PCSK9 content. Conclusions: Human platelets contain endogenous PCSK9 and can accumulate additional PCSK9 from the extracellular environment. Exogenous PCSK9 enhances platelet aggregation, supporting a potential prothrombotic role for circulating PCSK9 even in normolipidemic individuals. These findings provide new insight into the complex interplay between PCSK9, lipoproteins, and platelet function.
- 25 February 2026
- Published by MDPI AG in Lipidology
- Vol. 3 (1) , 8
Open AccessThe Effect of Lipoproteins on Platelet-Associated PCSK9 of Healthy Normolipidemic Volunteers: An In Vitro Study
Background: Proprotein convertase subtilisin/kexin type 9 (PCSK9) promotes low-density lipoprotein receptor degradation and thereby regulates plasma LDL cholesterol levels. Although PCSK9 is primarily produced by the liver, it has been detected in platelets; however, the origin and functional relevance of platelet-associated PCSK9 remain unclear. Methods: Washed platelets (WPs) were isolated from normolipidemic subjects. Endogenous platelet PCSK9 content was quantified by ELISA, and PCSK9 molecular forms were assessed by immunoblotting. The WPs were incubated with recombinant PCSK9 (recPCSK9), and platelet aggregation in response to arachidonic acid (AA) or thrombin (Thr) was evaluated. The effects of LDL- or HDL-bound PCSK9 on platelet aggregation were also examined. Results: Platelets from normolipidemic subjects contained measurable amounts of PCSK9 (0.84 ± 0.27 ng/mg protein), which increased to 2.91 ± 0.53 ng/mg protein following incubation with recPCSK9. Exposure to recPCSK9 significantly enhanced AA- and Thr-induced platelet aggregation. In contrast, LDL and HDL inhibited platelet aggregation independently of their PCSK9 content. Conclusions: Human platelets contain endogenous PCSK9 and can accumulate additional PCSK9 from the extracellular environment. Exogenous PCSK9 enhances platelet aggregation, supporting a potential prothrombotic role for circulating PCSK9 even in normolipidemic individuals. These findings provide new insight into the complex interplay between PCSK9, lipoproteins, and platelet function.
- Open Access
- 12 December 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (24) , 13343
Ticagrelor Induces Angiogenesis in Progenitor and Mature Endothelial Cells In Vitro: Investigation of the Possible Role of Adenosine
Ticagrelor, a reversible platelet P2Y12 receptor antagonist, exerts various pleiotropic actions, some of which are at least partially mediated through adenosine. We studied the ticagrelor and adenosine effect on the angiogenic properties of progenitor CD34+-derived endothelial colony-forming cells (ECFCs). Angiogenesis studies were performed in vitro using capillary-like tube formation and spheroid-based angiogenesis assays. The effects of adenosine receptor antagonists, including DPCPX (A1 antagonist), SCH58621 (A2A antagonist), MRS1706 (A2B inverse agonist and antagonist), MRS1220 (A3 antagonist) and adenosine deaminase (ADA), were also investigated. Ticagrelor, adenosine, and their combination increased capillary-like tube formation and spheroid sprout formation by ECFCs in a dose-dependent manner. This effect was significantly reduced by SCH58621, MRS1706, and their combination, as well as by ADA. By contrast, DPCPX and MRS1220 did not exhibit any inhibitory effects. Similar results were obtained when mature human umbilical vein endothelial cells (HUVECs) were studied. These results show that ticagrelor stimulates angiogenesis by progenitor and mature endothelial cells in an adenosine-dependent pathway in which the adenosine receptors A2A and A2B play major roles. The significance of these results at the clinical level in patients with atherothrombotic events and treated with ticagrelor needs to be investigated.
- 12 December 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (24) , 13343
Open AccessTicagrelor Induces Angiogenesis in Progenitor and Mature Endothelial Cells In Vitro: Investigation of the Possible Role of Adenosine
Ticagrelor, a reversible platelet P2Y12 receptor antagonist, exerts various pleiotropic actions, some of which are at least partially mediated through adenosine. We studied the ticagrelor and adenosine effect on the angiogenic properties of progenitor CD34+-derived endothelial colony-forming cells (ECFCs). Angiogenesis studies were performed in vitro using capillary-like tube formation and spheroid-based angiogenesis assays. The effects of adenosine receptor antagonists, including DPCPX (A1 antagonist), SCH58621 (A2A antagonist), MRS1706 (A2B inverse agonist and antagonist), MRS1220 (A3 antagonist) and adenosine deaminase (ADA), were also investigated. Ticagrelor, adenosine, and their combination increased capillary-like tube formation and spheroid sprout formation by ECFCs in a dose-dependent manner. This effect was significantly reduced by SCH58621, MRS1706, and their combination, as well as by ADA. By contrast, DPCPX and MRS1220 did not exhibit any inhibitory effects. Similar results were obtained when mature human umbilical vein endothelial cells (HUVECs) were studied. These results show that ticagrelor stimulates angiogenesis by progenitor and mature endothelial cells in an adenosine-dependent pathway in which the adenosine receptors A2A and A2B play major roles. The significance of these results at the clinical level in patients with atherothrombotic events and treated with ticagrelor needs to be investigated.
- Open Access
- 21 September 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (18) , 10136
Differential Effect of Omega-3 Fatty Acids on Platelet Inhibition by Antiplatelet Drugs In Vitro
The omega-3 polyunsaturated fatty acids (PUFAs) Docosahexaenoic acid (DHA) and Eicosapentaenoic acid (EPA) exert multiple cardioprotective effects, influencing inflammation, platelet activation, endothelial function and lipid metabolism, besides their well-established triglyceride lowering properties. It is not uncommon for omega-3 PUFAs to be prescribed for hypertriglyceridemia, alongside antiplatelet therapy in cardiovascular disease (CVD) patients. In this regard, we studied the effect of EPA and DHA, in combination with antiplatelet drugs, in platelet aggregation and P-selectin and αIIbβ3 membrane expression. The antiplatelet drugs aspirin and triflusal, inhibitors of cyclooxygenase-1 (COX-1); ticagrelor, an inhibitor of the receptor P2Y12; vorapaxar, an inhibitor of the PAR-1 receptor, were combined with DHA or EPA and evaluated against in vitro platelet aggregation induced by agonists arachidonic acid (AA), adenosine diphosphate (ADP) and TRAP-6. We further investigated procaspase-activating compound 1 (PAC-1) binding and P-selectin membrane expression in platelets stimulated with ADP and TRAP-6. Both DHA and EPA displayed a dose-dependent inhibitory effect on platelet aggregation induced by AA, ADP and TRAP-6. In platelet aggregation induced by AA, DHA significantly improved acetylsalicylic acid (ASA) and triflusal’s inhibitory activity, while EPA enhanced the inhibitory effect of ASA. In combination with EPA, ASA and ticagrelor expressed an increased inhibitory effect towards ADP-induced platelet activation. Both fatty acids could not improve the inhibitory effect of vorapaxar on AA- and ADP-induced platelet aggregation. In the presence of EPA, all antiplatelet drugs displayed a stronger inhibitory effect towards TRAP-6-induced platelet activation. Both omega-3 PUFAs inhibited the membrane expression of αIIbβ3, though they had no effect on P-selectin expression induced by ADP or TRAP-6. The antiplatelet drugs exhibited heterogeneity regarding their effect on P-selectin and αIIbβ3 membrane expression, while both omega-3 PUFAs inhibited the membrane expression of αIIbβ3, though had no effect on P-selectin expression induced by ADP or TRAP-6. The combinatory effect of DHA and EPA with the antiplatelet drugs did not result in enhanced inhibitory activity compared to the sum of the individual effects of each component.
- 21 September 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (18) , 10136
Open AccessDifferential Effect of Omega-3 Fatty Acids on Platelet Inhibition by Antiplatelet Drugs In Vitro
The omega-3 polyunsaturated fatty acids (PUFAs) Docosahexaenoic acid (DHA) and Eicosapentaenoic acid (EPA) exert multiple cardioprotective effects, influencing inflammation, platelet activation, endothelial function and lipid metabolism, besides their well-established triglyceride lowering properties. It is not uncommon for omega-3 PUFAs to be prescribed for hypertriglyceridemia, alongside antiplatelet therapy in cardiovascular disease (CVD) patients. In this regard, we studied the effect of EPA and DHA, in combination with antiplatelet drugs, in platelet aggregation and P-selectin and αIIbβ3 membrane expression. The antiplatelet drugs aspirin and triflusal, inhibitors of cyclooxygenase-1 (COX-1); ticagrelor, an inhibitor of the receptor P2Y12; vorapaxar, an inhibitor of the PAR-1 receptor, were combined with DHA or EPA and evaluated against in vitro platelet aggregation induced by agonists arachidonic acid (AA), adenosine diphosphate (ADP) and TRAP-6. We further investigated procaspase-activating compound 1 (PAC-1) binding and P-selectin membrane expression in platelets stimulated with ADP and TRAP-6. Both DHA and EPA displayed a dose-dependent inhibitory effect on platelet aggregation induced by AA, ADP and TRAP-6. In platelet aggregation induced by AA, DHA significantly improved acetylsalicylic acid (ASA) and triflusal’s inhibitory activity, while EPA enhanced the inhibitory effect of ASA. In combination with EPA, ASA and ticagrelor expressed an increased inhibitory effect towards ADP-induced platelet activation. Both fatty acids could not improve the inhibitory effect of vorapaxar on AA- and ADP-induced platelet aggregation. In the presence of EPA, all antiplatelet drugs displayed a stronger inhibitory effect towards TRAP-6-induced platelet activation. Both omega-3 PUFAs inhibited the membrane expression of αIIbβ3, though they had no effect on P-selectin expression induced by ADP or TRAP-6. The antiplatelet drugs exhibited heterogeneity regarding their effect on P-selectin and αIIbβ3 membrane expression, while both omega-3 PUFAs inhibited the membrane expression of αIIbβ3, though had no effect on P-selectin expression induced by ADP or TRAP-6. The combinatory effect of DHA and EPA with the antiplatelet drugs did not result in enhanced inhibitory activity compared to the sum of the individual effects of each component.
- Open Access
- 5 September 2022
- Published by Elsevier in Journal of Lipid Research
- Vol. 63 (10) , 100272
PCSK9 is minimally associated with HDL but impairs the anti-atherosclerotic HDL effects on endothelial cell activation
- 5 September 2022
- Published by Elsevier in Journal of Lipid Research
- Vol. 63 (10) , 100272
Open AccessPCSK9 is minimally associated with HDL but impairs the anti-atherosclerotic HDL effects on endothelial cell activation
- Top Cited Papers
- 1 September 2022
- Published by Bentham Science Publishers Ltd. in Current Medicinal Chemistry
- Vol. 29 (34) , 5496-5509
Inflammation, Oxidative Stress, Vascular Aging and Atherosclerotic Ischemic Stroke
Vascular aging is a crucial risk factor for atherosclerotic ischemic stroke. Vascular aging is characterized by oxidative stress, endothelial dysfunction, inflammation, intimal and media thickening, as well as the gradual development of arterial stiffness, among other pathophysiological features. Regarding oxidative stress, increased concentration of reactive oxygen and nitrogen species is linked to atherosclerotic ischemic stroke in vascular aging. Additionally, oxidative stress is associated with an inflammatory response. Inflammation is related to aging through the “inflammaging” theory, which is characterized by decreased ability to cope with a variety of stressors, in combination with an increased pro-inflammatory state. Vascular aging is correlated with changes in cerebral arteries that are considered predictors of the risk for atherosclerotic ischemic stroke. The aim of the present review is to present the role of oxidative stress and inflammation in vascular aging, as well as their involvement in atherosclerotic ischemic stroke.
- 1 September 2022
- Published by Bentham Science Publishers Ltd. in Current Medicinal Chemistry
- Vol. 29 (34) , 5496-5509
Top Cited PapersInflammation, Oxidative Stress, Vascular Aging and Atherosclerotic Ischemic Stroke
Vascular aging is a crucial risk factor for atherosclerotic ischemic stroke. Vascular aging is characterized by oxidative stress, endothelial dysfunction, inflammation, intimal and media thickening, as well as the gradual development of arterial stiffness, among other pathophysiological features. Regarding oxidative stress, increased concentration of reactive oxygen and nitrogen species is linked to atherosclerotic ischemic stroke in vascular aging. Additionally, oxidative stress is associated with an inflammatory response. Inflammation is related to aging through the “inflammaging” theory, which is characterized by decreased ability to cope with a variety of stressors, in combination with an increased pro-inflammatory state. Vascular aging is correlated with changes in cerebral arteries that are considered predictors of the risk for atherosclerotic ischemic stroke. The aim of the present review is to present the role of oxidative stress and inflammation in vascular aging, as well as their involvement in atherosclerotic ischemic stroke.